Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer.

Perioperative adjuvant treatment has become an increasingly important aspect of the management of patients with non-small cell lung cancer (NSCLC). In particular, the success of immune checkpoint inhibitors, such as antibodies against PD-1 and PD-L1, in patients with lung cancer has increased our expectations for the success of these therapeutics as neoadjuvant immunotherapy. Neoadjuvant therapy is widely used in patients with resectable stage IIIA NSCLC and can reduce primary tumor and lymph node stage, improve the complete resection rate, and eliminate microsatellite foci; however, complete pathological response is rare.

Modulation index dependence of intensity modulation bandwidth in visible light communications.

The modulation bandwidth of a light-emitting diode is inversely proportional to the carrier lifetime, which changes with varying injected current. However, in conventional implementations of visible light communications, the influence of bias current is always emphasized, while the effects of modulation indices and signal components are ignored. In this Letter, it is the first time, to the best of our knowledge, that the mechanism on how modulated signal components impact modulation bandwidth is clarified.